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Abstract 
Background: Bipolar disorder (BD) is a psychiatric disorder with an uncertain aetiology. Recently, 
special attention has been given to homocysteine (Hcy), as it has been suggested that alterations 
in 1-carbon metabolism might be implicated in diverse psychiatric disorders. However, there is 
uncertainty regarding possible alterations in peripheral Hcy levels in BD.  
Methods: This study comprises a meta-analysis comparing serum and plasma Hcy levels in 
persons with BD and healthy controls. We conducted a systematic search for all eligible English 
and non-English peer-reviewed articles.  
Results: Nine cross-sectional studies were included in the meta-analyses, providing data on 1547 
participants. Random-effects meta-analysis showed that serum and plasma levels of Hcy were 
increased in subjects with BD in either mania or euthymia when compared to healthy controls, 
with a large effect size in the mania group (g = 0.98, 95% CI 0.8 to 1.17, p < 0.001, n = 495) and 
a small effect in the euthymia group (g = 0.3, 95% CI 0.11 to 0.48, p = 0.002, n = 1,052). 
Conclusions: Our meta-analysis provides evidence that Hcy levels are elevated in persons with 
BD during mania and euthymia. Peripheral Hcy could be considered as a potential biomarker in 
BD, both of trait (since it is increased in euthymia), and also of state (since its increase is more 
accentuated in mania). Longitudinal studies are needed to clarify the relationship between 
bipolar disorder and Hcy, as well as the usefulness of peripheral Hcy as both a trait and state 
biomarker in BD.  
1. Introduction 
In order to better understand the physiopathology underlying bipolar disorder (BD),  increasing 
research efforts have attempted to identify potential biomarkers in the peripheral blood of 
those with BD and also to advance the elusive field of precision psychiatry [1-4]. Neurotrophins 
such as BDNF [5-9] and inflammatory markers such as C-reactive protein [10-12] have 
consistently been proposed as promising peripheral biomarkers in BD. More recently, special 
attention is being given to homocysteine (Hcy) (Ghanizadeh et al.), as it has been suggested that 
alterations in 1-carbon metabolism might be implicated in psychiatric disorders, including BD 
[13-16].  
 
In the 1-carbon metabolism, a carbon unit from serine or glycine is transferred to 
tetrahydrofolate (THF) to form methylene-THF. Homocysteine is a non-protein and nonessential 
amino acid sulfur with a central role in 1-carbon metabolism, and its regulation depends on 
multiple enzymes, with methylenetetrahydrofolate reductase (MTHFR) the most extensively 
investigated. Folate and vitamin B12 are also key elements of Hcy metabolism, since they act as 
enzymatic cofactors [17, 18]. Accordingly, either a reduced enzymatic activity of MTHFR or a 
nutritional deficiency in folate or vitamin B12 may lead to hyperhomocysteinemia [18-20]. This 
may promote neurotoxic and vasculotoxic effects by several proposed mechanisms, including 
but not limited to mitochondrial dysfunction [21], oxidative stress induction [13, 22, 23], 
inflammation [24], neuroapoptosis [25, 26], direct vascular damage [24, 27], aberrant DNA 
methylation [28, 29] and impaired DNA synthesis [30]. These pathways overlap considerably 
with those pathways documented as drivers of the process of neuroprogression evident in BD. 
Equally, this is concordant with the notion of shared pathways to comorbidity of both psychiatric 
and common medical disorders. 
 
Hyperhomocysteinemia is a known risk factor for cardiovascular diseases [31] and Alzheimer’s 
dementia [32, 33]. Additionally, several studies have described an association between higher 
levels of Hcy and depression [34-38], autism [39] and schizophrenia [16, 28, 40]. In addition, a 
recent meta-analysis by Numata et al. provided evidence that increased Hcy levels is causally 
related with an increased risk of developing schizophrenia using a Mendelian Randomization 
analysis [15]. In BD, higher levels of peripheral Hcy have been associated with worse cognitive 
performance [41, 42]. 
 
Contrary to schizophrenia, where better evidence exists, data on peripheral levels of Hcy in BD 
are more limited, with discrepant findings across studies conducted to date; some studies show 
increased levels of Hcy in persons with BD when compared to healthy controls [43], while others 
find no evidence for this association [44]. The aim of this study was therefore to verify if 
alterations in peripheral Hcy levels are present in BD in the different mood states compared to 
healthy controls. To this end, we performed a meta-analysis of all available cross-sectional 
studies that measured peripheral Hcy levels in BD compared to healthy subjects in order to 
evaluate the potential of Hcy as a biomarker in BD. The null hypothesis was that there would be 
no difference between individuals with BD compared to healthy controls.  
 
  
2. Methods  
We performed a meta-analysis comparing peripheral levels of Hcy in subjects with BD across 
different mood states versus healthy controls. We adhered to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) statement and guidelines from the Cochrane 
Collaboration [45]. The literature search, decisions on inclusion, data extraction and quality 
control were all independently performed by two of the authors (ES, BSF). Disagreements were 
resolved through consensus. An a priori defined but unpublished protocol was followed.   
 
2.1. Search strategy 
We conducted a systematic search for all potentially eligible peer-reviewed articles using 
PubMed and SCOPUS on January 2016. We included studies published in English, Dutch, French, 
German, Italian, Portuguese and Spanish, with no year or country restrictions [45]. The Boolean 
terms used for the electronic database search were: (homocysteine OR MTHFR OR 
methylenetetrahydrofolate reductase OR folate OR folic acid OR B12) AND (bipolar OR mania 
OR psychosis). We manually searched bibliographies of the identified articles in order to identify 
further relevant references that might have been missed in the initial search. Study selection 
eligibility and exclusion criteria were pre-specified.  
 
2.2. Study selection 
We included studies meeting the following inclusion criteria: 1) adult subjects with diagnosis of 
BD, as defined by Diagnostic and Statistical Manual of Mental Disorders (DSM), regardless of 
current mood state; 2) pairwise comparison with a control group of healthy volunteers; and 3) 
studies that assessed homocysteine levels in vivo. Exclusion criteria were: 1) duplicate reports; 
2) studies conducted in subjects aged less than 18 years; 3) reviews or meta-analyses articles; 4) 
lack of a control group of healthy volunteers; 5) genetic studies not measuring Hcy levels; 6) 
studies that included samples with mixed psychiatric diagnoses unless data for BD were reported 
separately or were obtained after contacting the authors; 7) studies not specifying the mood 
state of the subjects at the time Hcy was assessed; 8) studies which did not report data on 
subjects with BD separately according to mood state; and 9) animal studies. 
 
We used the Newcastle–Ottawa Scale (NOS) for case-control studies [46] as recommended by 
the Cochrane Collaboration [47] to assess the quality of the eligible studies. Overall quality score 
was defined as the frequency of criteria that were met by the particular study. The NOS scale 
contains eight items in the case-control, categorised into the three domains of selection, 
comparability, and exposure.  A series of response options is provided for each item. A star 
system was used to enable semi-quantitative assessment of study quality, such that the highest 
quality studies are awarded a maximum of one star for each item, with the exception of the 
comparability domain, which allows the assignment of two stars. As such, the Newcastle-Ottawa 
scale ranges between zero and nine stars [46]. Item “non-response rate” from Exposure in the 
case-control scale was not applicable; therefore, a maximum of eight stars was considered. The 
quality score of the included were four and five. All studies were included in the posterior 
analyses. 
 
2.3. Data extraction 
Two independent reviewers extracted data [n, mean and standard deviation (SD)] using a 
predesigned form [45]. Whenever necessary, authors of included studies were electronically 
contacted to provide data in at least two separate occasions. Whenever data on the same 
participants were provided by different articles, only the most comprehensive data set was 
included. When necessary, means and SD were calculated from available graphs using 
procedures described in details elsewhere [48]. 
 
All variables were extracted separately for each mood state (euthymia, mania or depression). 
We extracted the following data: sample size, age, sex, length of illness in years, body mass index 
(BMI), smoking status, mean score of the Hamilton Depression Rating Scale (HDRS) [49] and the 
Young Mania Rating Scale (YMRS) [50], medications in use, study population, type of assay, and 
sampling source (plasma or serum). 
 
2.4. Publication bias 
Studies with negative (i.e., non-significant) results are less likely to be published than studies 
with positive (i.e., statistically significant) results. To account for potential publication bias, an 
acknowledged problem in the field of peripheral biomarkers in psychiatric disorders including 
BD and major depressive disorder [51, 52], we inspected funnel plot graphs, which are scatter 
plots of the effect size (ES) against a measure of study sample size, and the Egger’s regression 
test [53]. In addition, the Orwin's fail-safe N test (file drawer statistic) was used to quantify the 
number of possible negative omitted studies that would be required to render statistically 
significant results non-significant (i.e., p > 0.05) [54].  
 
2.5. Statistical analysis 
Our primary aim was to quantify differences in peripheral Hcy levels in persons with BD 
compared to healthy volunteers. We will address this according to mood state because. We 
employed Comprehensive Meta-Analysis Software (CMA) version 2.0 in all analyses. Since 
eligible studies included different assay methods, we used standardized mean differences to 
estimate differences in peripheral Hcy levels in individuals with BD compared to healthy 
controls. We used Hedges’ adjusted g, as it provides a relatively unbiased ES estimate adjusted 
for sample size. We also calculated the 95% confidence interval (95% CI) of the ES. An ES of 0.2 
was considered as a small ES, i.e., it indicates a small difference in Hcy levels between subjects 
with BD and controls, while an ES of 0.5 was considered as a moderate effect and an ES ≥ 0.8 as 
a large effect [55]. The direction of the ES values was negative if subjects with BD showed 
decreased Hcy levels when compared to healthy controls, and positive if they showed increased 
Hcy levels. 
 
Heterogeneity across studies was assessed using the Cochran Q test, a weighted sum of the 
squares of the deviations of individual study ES estimates from the summary ES estimate, and a 
p value of < 0.10 was considered significant (i.e., indicating heterogeneity). Inconsistency across 
studies was also evaluated using the I2 metric, which describes the percentage of the variability 
in effect estimates that is due to heterogeneity rather than sampling error. An I2 > 50% is 
considered indicative of substantial heterogeneity [45]. 
 
Both measures of heterogeneity (i.e., the Cochran Q test and the I2 metric) have a limited power 
to detect heterogeneity unless very large data sets are available. Thus, we pooled ES estimates 
of individual studies using random-effects modelling, which allows population-level inferences 
and is more stringent than fixed-effects models. Random-effects models assume that the true 
effect size differs across studies and incorporates a between-study variance into the calculations 
[45, 56].  
 
Unrestricted maximum likelihood random-effects meta-regressions of ES were performed in 
euthymic subjects, with mean age and percentage of female sex as moderators, to determine 
whether these covariates influenced the ES. Meta-regression analyses with data from fewer 
than five datasets may provide spurious findings [45]. Therefore, we explored potential sources 
of heterogeneity with this tool only when independent data from at least five studies were 
available. Studies were weighted such that the studies with the most precise parameters, 
quantified by the sample size and 95% CI, had more influence in the regression analyses.  
The meta-analyses consisted of three steps. Firstly, we performed the meta-analyses according 
to mood state. As only a single study assessing Hcy levels in BD subjects with a depressive 
episode was identified [57], we limited our analyses to mania and euthymia. Secondly, sensitivity 
analyses were conducted to ascertain whether the results of our analyses were strongly 
influenced by any single study or studies sharing some characteristics. The overall significance 
was recomputed after each study or group of studies with a common feature were deleted from 
the analysis. Thirdly, we performed meta-regression analyses in order to investigate possible 
moderators of Hcy levels. The level of significance was set at p< 0.05. 
  
  
3. RESULTS 
In total, 2597 studies were identified through the systematic electronic search. Of those, we 
excluded 2540 on the basis of title and abstract. We went through 57 full-text articles of which: 
two were excluded because they were duplicates with overlapping samples [58, 59]; eighteen 
studies were excluded because they lacked a control group [35, 43, 60-75]; twelve were 
excluded because they were not performed in subjects with a diagnosis of BD [38, 76-86]; twelve 
were excluded because they did not measure Hcy levels [87-98]; and two were excluded because 
they presented mixed data on BD and other psychiatric disorders [99, 100]. The authors of a 
study that analysed together the total mean Hcy level for subjects with BD in different mood 
states were contacted to request mean Hcy levels separately according to mood states. Since no 
response was provided, this article was also excluded [101]. In total, we identified 10 studies 
fulfilling our inclusion criteria, of which two studies measured Hcy levels in mania (227 persons 
with BD and 268 healthy controls) [102, 103], eight in euthymia (436 persons with BD and 616 
healthy controls) [41, 58, 103-108] and one in depression [57] (Figure 1). As there was only one 
article assessing Hcy levels in persons with BD in depression, which found no differences in Hcy 
levels between persons with BD and the control group [57], a meta-analysis could not be 
conducted. All studies included in the analyses were cross-sectional and they provided data on 
1547 participants; of these, 663 comprised subjects with BD and 884 were healthy controls. One 
study [103] provided more than one pairwise comparison.  
 
The characteristics of the included studies are summarized in Table 1. The studies were 
published from 2004 to 2013. They included participants of either sex with a mean age between 
33.6 and 49.8. The diagnosis of bipolar disorder was made according to the DSM-IV. Severity of 
affective symptoms were assessed with the YMRS for manic symptoms and the HDRS for 
depressive symptoms. Only one study provided data on YMRS in the mania group [103] and the 
median score was 27.5 (19-30.7). The euthymia group was defined as scoring less than 6 on the 
YMRS and less than 8 on the HDRS across studies.  
In six of the nine studies, the control group was matched by sex and age [58, 87, 103-105, 108].  
All subjects with BD were on psychopharmacological treatment. Seven studies provided details 
on the medications used [58, 102, 104-108], the most common being mood stabilizers, 
antidepressants, and first and second generation antipsychotics. All studies excluded subjects 
with either long-term somatic conditions or substance use disorders.  
 
3.1. Hcy levels are increased in BD compared to healthy controls  
We included two studies in the meta-analysis of Hcy levels in subjects with BD in manic state 
compared with healthy controls [102, 103] and eight studies in the meta-analysis that compared 
subjects with BD in euthymic state compared with healthy controls [41, 58, 103-108]. Random-
effects meta-analysis showed that serum and plasma levels of Hcy were increased in subjects 
with BD either in mania or in euthymia when compared to healthy controls, with a large effect 
in the mania group (g = 0.98, 95% CI 0.80 to 1.17, p < 0.001, 2 between-group comparisons, n = 
495) and a small effect in the euthymia group (g = 0.30, 95% CI 0.11 to 0.48, p = 0.002, 8 
between-group comparisons, n = 1,052) (Figure 2, Table 2).   
 
3.2. Hcy levels in BD are not associated with age or sex  
We performed meta-regression analyses to identify possible effect moderators. Since there 
were a small number of studies assessing Hcy in mania, we only performed the meta-regression 
analyses for the euthymia group. In univariable meta-regression models for euthymia, we found 
that neither age (slope = -0.01, 95% CI -0.04 to 0.03, p = 0.711) nor sex (slope = 0.001, 95% CI -
0.02 to 0.02, p= 0.943) were related to the difference in Hcy levels in euthymia between those 
with BD and controls (Table 2).  
 
3.3. Sensitivity analyses and publication bias   
We found no heterogeneity between studies performed in persons with BD in manic state (I2 = 
0%, p = 0.39). In contrast, heterogeneity was moderate between studies performed in euthymia 
(I2 = 43.3%, p = 0.09). To examine potential sources of heterogeneity detected in the euthymia 
group, we conducted sensitivity analysis. We excluded studies one at a time, in order to define 
its individual influence on the estimated overall effect and, therefore, determine the robustness 
of the analyses, and we did not find any particular study being responsible for heterogeneity in 
the euthymia group.  
 
In addition, we found no evidence of publication bias on the funnel plot. The trim-and-fill 
estimate did not suggest any missing studies and the Orwin's fail-safe N test suggested that 148 
negative missing studies would be necessary to turn our statistically significant results non-
significant [54]. 
  
4. Discussion 
 
Our results indicate that higher Hcy levels are found in persons with BD in manic and euthymic 
states when compared to healthy controls. The meta-regression analyses performed in the 
euthymia group showed that these differences were not significantly moderated by age or sex. 
This is the first meta-analysis to assess peripheral Hcy as a putative biomarker in BD.  
 
Although there is growing literature showing an association between increased Hcy levels and 
psychiatric disorders, the nature of this relationship remains unclear. The role of Hcy in the 
Central Nervous System (CNS) is complex, as it participates in a large number of processes. It has 
been proposed that an alteration in glutamatergic neurotransmission may be a main mechanism 
linking Hcy and psychiatric disorders, including BD [18, 109]. Homocysteine and its related 
compounds may have a role as a partial excitatory agonist on the N-Methyl-D-aspartate (NMDA) 
subtype of glutamate receptors and also on modulatory sites. Thus, long-term activation of 
NMDA receptors due to hyperhomocysteinemia would result in an increased calcium ion influx, 
elevated intracellular second messenger calcium, and accumulation of reactive oxygen species 
and, ultimately, would lead to cell damage and induction of both apoptotic and necrotic cell 
death. [18, 25, 110]. Higher Hcy levels induced by methylenetetrahydrofolate reductase 
deficiency alters glutamatergic and GABAergic levels and contributes to neurotoxicity in the CNS 
[111].  
 
It has also been hypothesized that long exposure to excessive levels of Hcy in the CNS can 
activate inflammatory pathways involving oxidative stress and pro-inflammatory cytokines, 
producing neural toxicity and microvascular damage [19, 44, 112, 113]. Moreover, the brain 
depends on the 1-carbon metabolism to obtain methyl groups, with homocysteine acting as a 
methyl donor through its transformation to S-adenosylmethionine (SAMs), which is the main 
methyl donor in the CNS [17, 30]. Hence, dysregulation of the 1-carbon metabolism may 
promote aberrant DNA methylation, which has as well been proposed as a potential mechanism 
involved in the development of psychiatric illnesses, including BD [104, 114]. Finally, the 1-
carbon metabolism also participates in monoamine regulation, so alterations in Hcy metabolism 
could lead to inadequate monoamine production and, consequently to dysregulation of 
serotonin, norepinephrine and dopamine [30, 44]. Hyperhomocysteinemia may interfere with 
cholinergic metabolism by reducing choline acetyltransferase activity in some neuronal 
populations potentially leading to cognitive effects [115]. This perhaps suggests that 
pharmacological interventions capable of decreasing Hcy levels could be beneficial in BD. Folate 
and vitamin B12 are key elements of Hcy metabolism, since they act as enzymatic cofactors that 
decrease Hcy production, with folate and vitamin B12 being cofactors for the methylation of Hcy 
into methionine and tetrahydrofolate (THF), which is the immediate acceptor of 1-carbon units 
for the synthesis of thymidine, purines (RNA and DNA), and methionine [17, 18]. However, the 
benefit of prescribing folate to patients with depression without folate deficiency is 
controversial. One clinical trial found that folate supplementation using folic acid, the most 
commonly employed form of pharmacological supplementation, did not decrease the 
occurrence of depression in young people with increased risk of mood disorders, although it 
delayed the occurrence of the first episode of depression [116], and a clinical trial with 475 
persons with an acute unipolar major depressive episode without vitamin deficiencies showed 
no benefit with folate [117]. A recent meta-analysis confirmed no short-term benefit of folate 
or B12 supplementation for depression, although there was a suggestion of a possible long-term 
benefit to prevent incidence or relapse [118]. 
 
However, this lack of effect might be due to the fact that the blood-brain barrier (BBB) is 
relatively impermeable to folic acid and folate, therefore the effect of supplementation with 
folic acid might only appear after several months, with a slow and cumulative effect of folate 
[119]; it has been hypothesised that probably methylfolate, the biologically active form of folate 
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that can freely cross the BBB and cell membranes and that is also the predominant form of folate 
acquired through diet, would be a better choice as a pharmacological treatment. In addition, 
folic acid, the synthetic form of folate employed in abovementioned studies, needs to undergo 
enzymatic reduction by the enzyme dihydrofolate reductase (DHFR) in order to become 
biologically active within the cell [120].  Also, one clinical trial suggested that folic acid can 
significantly reduce the effect of lamotrigine in bipolar depression [121]. Consequently, 
methylfolate may be associated with a reduced interaction with drugs that inhibit dihydrofolate 
reductase, such as is the case with lamotrigine, than folic acid [120]. 
 
It is possible that the direction of the association between BD and Hcy is reversed, meaning that 
BD leads to increased Hcy levels, and not the opposite. It is also possible that confounders 
associated with both BD and Hcy play a role in the findings of increased Hcy levels in BD. Most 
likely, the reality is a combination of these three scenarios.  It is also worth noting that low levels 
of physical activity are associated with elevated Hcy levels [122], and persons with BD are known 
to be more sedentary than healthy controls [123].  Exercise interventions, particularly resistance 
exercise, can reduce Hcy levels [124], and future research may wish to consider if exercise can 
reduce Hcy levels, cardiovascular risk and improve other health parameters in people with BD 
[125].   
 
Although older age has been linked to higher levels of Hcy [20, 110, 126], linked to dietary 
factors, our meta-regression analyses found no relationship between age and Hcy levels in 
persons with BD in euthymia. This might suggest that higher levels of Hcy may be present since 
the beginning of the illness at a younger age in BD, independently of environmental factors. This 
is in line with the results of Misiak et al., who found that Hcy plasma levels were significantly 
higher in first episode schizophrenia patients than in healthy controls [127].  Likewise, higher 
levels of Hcy have been described in males compared to females with BD [72], which suggests a 
potentially protective role of estrogens amongst many other biological and social factors [128]. 
Nevertheless, sex did not emerge as a significant moderator in our meta-regression analyses.  
Finally, the new field of research focused on the microbiome-gut-brain axis in psychiatry may be 
of relevance [129]. Gut microbiota synthesise B-group Vitamins [130] and maladaptive 
metabolism of these vitamins may be a function of microbiota dysbiosis, which in turn may be 
both cause and consequence of mood disorders [131]. As this field develops, more insights into 
the possible mechanistic pathways between microbes and the brain will possibly emerge; given 
the modifiable nature of the gut microbiota, this may yield new targets for intervention [132]. 
 
4.1. Strengths and limitations 
Our study has some strengths and limitations that deserve discussion. Firstly, we included a 
relatively small number of studies with a cross-sectional design, which does not allow inferring 
of causality, besides having other potential limitations such as confounding and selection bias. 
However, we found no evidence of heterogeneity across studies performed in persons with BD 
in mania and moderate heterogeneity between studies performed in euthymia. A strength of 
this meta-analysis is that we found no evidence of publication bias, a common issue with 
biomarkers in psychiatric disorders such as BD [52] and major depressive disorder [51], as the 
funnel plot was symmetric. In addition, we estimated that 148 missing studies with null results 
would be necessary to turn our significant results into negative ones.  In addition, due to the 
small number of available studies we were not able to analyse the relationship between 
depressive symptoms and Hcy as we only identify one article assessing this issue. Similarly, the 
limited number of identified studies for mania prevented us from conducting meta-regressions 
analysing possible associations between sex, age and Hcy levels in this subgroup. Another point 
is that Hcy levels are known to be influenced by several factors, including physical activity, 
numerous systemic illnesses, diet (especially vitamin B12 and folic acid levels), BMI, and 
smoking. As only a minority of studies provided data on these factors, we were not able to 
perform meta-regression analyses using them as moderators. Importantly, Hcy levels are also 
influenced by medications such as lamotrigine or valproate [19] and all the included patients 
were on pharmacological treatment. Fourthly, all studies determined Hcy levels in the periphery, 
but as it is known that Hcy metabolism pathways differ between the CNS and the periphery, it 
is not sure that peripheral Hcy levels are representative of central Hcy levels. Data on key 
genotype variants would also have been informative if available. It would similarly be valuable 
to have longitudinal data to determine if Hcy is a biomarker of trait or state in from a 
pathophysiological perspective, and if it also could be a biomarker with clinical value as a 
biomarker of response to treatment and/or prognosis, given that it will have adequate sensitivity 
and specificity. 
 
4.2. Conclusions  
Our meta-analysis provides evidence that Hcy levels are elevated in persons with BD in mania 
or euthymia independently of sex and age. These findings provide preliminary evidence that 
peripheral Hcy levels could be a potential biomarker in BD, both of trait (since it is increased in 
euthymia, and also of state (since its increase is more accentuated in mania). Larger longitudinal 
studies taking into account the confounding effect of the aforementioned variables and 
assessing patients in the different mood states are needed to clarify the relationship between 
bipolar disorder and Hcy as well as the clinical usefulness of peripheral Hcy as a biomarker for 
diagnosis, of response to treatment and/or prognosis. 
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LEGENDS 
 
Figure 1. Flow diagram of the systematic review, showing the study inclusion and exclusion 
process. Some studies included subjects in more than one mood state, being included in more 
than one analysis. 
 
Figure 2. Forest plot for random effects meta-analysis on serum and plasma homocysteine levels 
in persons with bipolar disorder compared to healthy controls.  
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